ENANTA PHARMACEUTICALS INC — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Enanta reported Q3 FY2026 revenue of $14.4M (down from $18.3M YoY) from AbbVie MAVYRET royalties, with net loss of $19.5M ($0.67/share). The company has $211.5M in cash and securities. Operationally, dosing began in LOTUS (Phase 2b pediatric RSV trial, ~150 patients, topline 2027), and RESOLVE (registrational Phase 2b/3 adult RSV trial) is on track for Q4 2026 initiation with Phase 2b data expected in 2027. Immunology programs advancing: EDP-978 Phase 1 (KIT inhibitor for urticaria, topline Q4 2026), EPS-3903 (STAT6 inhibitor, IND filing targeted H2 2026), and MRGPRX2 candidate selection targeted H2 2026.
Why this rating
Major clinical catalysts (registrational-stage RSV trial initiation, multiple 2027 readouts) advance pipeline materially; 2-year cash runway reduces dilution risk. Relative to $110.6M market cap, $211.5M cash and royalty base represent substantial backing, though royalty revenue declining 21% YoY is concerning. Event is material for trajectory but execution risk remains high.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.